Clinical Trial Update: Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial at MD Anderson is evaluating the combination of pembrolizumab with chemoradiotherapy for unresectable gastroesophageal junction adenocarc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | Status: ACTIVE_NOT_RECRUITING